11 completed, 1 terminated. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 11, Terminated 1 |
Follow eslicarbazepine acetate: new trials by email Literature Review of eslicarbazepine acetate trials Research Report on eslicarbazepine acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-epileptogenic Effects of Eslicarbazepine Acetate ESL 800 mg, Placebo - Post Stroke Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 129 | 2019-05-29 | 2025-05-02 |
| Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours ESL Banana taste, ESL Grape taste, ESL Tutti-Frutti taste - Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 38 | 2012-12-01 | 2014-04-03 |
| Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures Eslicarbazepine acetate (BIA 2-093), Placebo - Partial Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 123 | 2010-08-01 | 2014-10-24 |
| Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia Placebo, ESL 400 mg, ESL 800 mg - Fibromyalgia | Phase 2 | Completed | Bial - Portela C S.A. | 528 | 2009-04-01 | 2013-07-19 |
| Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine Placebo, ESL 1200 mg, ESL 800 mg - Migraine | Phase 2 | Completed | Bial - Portela C S.A. | 452 | 2009-04-01 | 2013-05-24 |
| Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Eslicarbazepine acetate, Placebo - Postherpetic Neuralgia | Phase 2 | Completed | Bial - Portela C S.A. | 567 | 2007-11-01 | 2014-10-29 |
| Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Eslicarbazepine acetate, Placebo - Painful Diabetic Neuropathy | Phase 2 | Completed | Bial - Portela C S.A. | 557 | 2007-11-01 | 2016-06-22 |
| Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder BIA 2-093 1800 mg once daily [Group 1 (Part II)], BIA 2-093 900 mg once daily [Group 2 (Part II)], BIA 2-093 300 mg once daily [Group 3 (Part II)] - Bipolar I Disorder | Phase 2 | Completed | Bial - Portela C S.A. | 104 | 2006-03-01 | 2014-03-27 |
| Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder Eslicarbazepine acetate 1800 mg, Eslicarbazepine acetate 1200 mg, Eslicarbazepine acetate 600 mg - BIPOLAR I DISORDER | Phase 2 | Terminated | Bial - Portela C S.A. | 38 | 2006-02-01 | 2014-03-27 |
| Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder Eslicarbazepine Acetate, Placebo - Bipolar I Disorder | Phase 2 | Completed | Bial - Portela C S.A. | 161 | 2005-12-01 | 2014-03-27 |
| Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 BIA 2-093 (Eslicarbazepine acetate) - Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 35 | 2005-06-01 | 2017-09-20 |
| A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 BIA 2-093, Placebo - Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 144 | 2002-04-01 | 2017-08-18 |
Epilepsy (4) · Diabetic Neuropathies (1) · Epilepsies, Partial (1) · Fibromyalgia (1) · Migraine Disorders (1) · Neuralgia, Postherpetic (1)
Italy (2) · Portugal (2) · Romania (2) · Austria (1) · France (1) · Germany (1) · Israel (1) · Netherlands (1) · Poland (1) · Russia (1) · Slovakia (1) · Spain (1) · Sweden (1) · Ukraine (1) · United Kingdom (1)
Patricio Soares-da-Silva, MD, PhD (2) · Eugen Trinka, MD MSc FRCP (1) · Matthias Koepp, MD PhD FRCP (1)
2018 (1)